NICE-squareThe NICE guidance for anti TNF therapy for ankylosing spondylitis is currently being reviewed. NICE are carrying out a Multiple Technology Appraisal on ‘Adalimumab, etanercept infliximab and golimumab for treating ankylosing spondylitis and non-radiographic axial spondyloarthritis’. NASS have made a submission and will be attending the first appraisal committee meeting on 25 February. Guidance is expected in July 2015.

Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) – adalimumab, etanercept infliximab and golimumab (inc rev TA143 and TA233) | Guidance and guidelines | NICE

Comments are closed.